Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
13/05/2024 | 22:05 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:DERM | Journey Medical Corporation |
13/05/2024 | 22:01 | GlobeNewswire Inc. | Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights | NASDAQ:DERM | Journey Medical Corporation |
07/05/2024 | 14:30 | GlobeNewswire Inc. | Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024 | NASDAQ:DERM | Journey Medical Corporation |
01/05/2024 | 22:01 | GlobeNewswire Inc. | Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer | NASDAQ:DERM | Journey Medical Corporation |
25/04/2024 | 14:30 | GlobeNewswire Inc. | Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024 | NASDAQ:DERM | Journey Medical Corporation |
21/03/2024 | 21:01 | GlobeNewswire Inc. | Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights | NASDAQ:DERM | Journey Medical Corporation |
18/03/2024 | 13:30 | GlobeNewswire Inc. | Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea | NASDAQ:DERM | Journey Medical Corporation |
15/03/2024 | 13:30 | GlobeNewswire Inc. | Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024 | NASDAQ:DERM | Journey Medical Corporation |
13/03/2024 | 13:30 | GlobeNewswire Inc. | Journey Medical Corporation to Participate in the 36th Annual ROTH Conference | NASDAQ:DERM | Journey Medical Corporation |
11/03/2024 | 13:30 | GlobeNewswire Inc. | Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting | NASDAQ:DERM | Journey Medical Corporation |
23/02/2024 | 23:54 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:DERM | Journey Medical Corporation |
05/01/2024 | 14:30 | GlobeNewswire Inc. | Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea | NASDAQ:DERM | Journey Medical Corporation |
02/01/2024 | 22:05 | GlobeNewswire Inc. | Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million | NASDAQ:DERM | Journey Medical Corporation |
15/12/2023 | 22:46 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:DERM | Journey Medical Corporation |
06/12/2023 | 14:00 | GlobeNewswire Inc. | Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea | NASDAQ:DERM | Journey Medical Corporation |
07/11/2023 | 22:01 | GlobeNewswire Inc. | Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights | NASDAQ:DERM | Journey Medical Corporation |
31/10/2023 | 13:30 | GlobeNewswire Inc. | Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023 | NASDAQ:DERM | Journey Medical Corporation |
20/10/2023 | 14:30 | GlobeNewswire Inc. | Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg) | NASDAQ:DERM | Journey Medical Corporation |
06/09/2023 | 14:00 | GlobeNewswire Inc. | Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian Nations | NASDAQ:DERM | Journey Medical Corporation |
14/08/2023 | 22:01 | GlobeNewswire Inc. | Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights | NASDAQ:DERM | Journey Medical Corporation |
10/08/2023 | 22:45 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:DERM | Journey Medical Corporation |
08/08/2023 | 22:01 | GlobeNewswire Inc. | Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights | NASDAQ:DERM | Journey Medical Corporation |
02/08/2023 | 22:01 | GlobeNewswire Inc. | Journey Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023 | NASDAQ:DERM | Journey Medical Corporation |
19/07/2023 | 14:30 | GlobeNewswire Inc. | Journey Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023 | NASDAQ:DERM | Journey Medical Corporation |
11/07/2023 | 14:30 | GlobeNewswire Inc. | Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults | NASDAQ:DERM | Journey Medical Corporation |
03/07/2023 | 14:00 | GlobeNewswire Inc. | Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of July | NASDAQ:DERM | Journey Medical Corporation |
23/06/2023 | 22:06 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:DERM | Journey Medical Corporation |
13/06/2023 | 14:30 | GlobeNewswire Inc. | Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult Subjects | NASDAQ:DERM | Journey Medical Corporation |
22/05/2023 | 22:01 | GlobeNewswire Inc. | Journey Medical Corporation Reports First Quarter 2023 Financial Results and Recent Corporate Highlights | NASDAQ:DERM | Journey Medical Corporation |
19/05/2023 | 22:01 | GlobeNewswire Inc. | Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 22, 2023 | NASDAQ:DERM | Journey Medical Corporation |